CA3230123A1 - Spiro indoline inhibitors of kif18a - Google Patents

Spiro indoline inhibitors of kif18a Download PDF

Info

Publication number
CA3230123A1
CA3230123A1 CA3230123A CA3230123A CA3230123A1 CA 3230123 A1 CA3230123 A1 CA 3230123A1 CA 3230123 A CA3230123 A CA 3230123A CA 3230123 A CA3230123 A CA 3230123A CA 3230123 A1 CA3230123 A1 CA 3230123A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
halo
cycloalkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3230123A
Other languages
English (en)
French (fr)
Inventor
Derek A. Cogan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volastra Therapeutics Inc
Original Assignee
Volastra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volastra Therapeutics Inc filed Critical Volastra Therapeutics Inc
Publication of CA3230123A1 publication Critical patent/CA3230123A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3230123A 2021-08-26 2022-08-25 Spiro indoline inhibitors of kif18a Pending CA3230123A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163237275P 2021-08-26 2021-08-26
US63/237,275 2021-08-26
US202263306452P 2022-02-03 2022-02-03
US63/306,452 2022-02-03
US202263344435P 2022-05-20 2022-05-20
US63/344,435 2022-05-20
PCT/US2022/075472 WO2023028564A1 (en) 2021-08-26 2022-08-25 Spiro indoline inhibitors of kif18a

Publications (1)

Publication Number Publication Date
CA3230123A1 true CA3230123A1 (en) 2023-03-02

Family

ID=83457176

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3230123A Pending CA3230123A1 (en) 2021-08-26 2022-08-25 Spiro indoline inhibitors of kif18a

Country Status (12)

Country Link
US (2) US12084420B2 (enExample)
EP (1) EP4392407A1 (enExample)
JP (1) JP2024534840A (enExample)
KR (1) KR20240109977A (enExample)
CN (1) CN119241504A (enExample)
AU (1) AU2022334480A1 (enExample)
CA (1) CA3230123A1 (enExample)
CL (1) CL2024000560A1 (enExample)
IL (1) IL310863A (enExample)
MX (1) MX2024002391A (enExample)
TW (1) TW202317092A (enExample)
WO (1) WO2023028564A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211475A1 (es) 2018-12-20 2021-08-05 Amgen Inc Inhibidores de kif18a
WO2024039829A1 (en) 2022-08-18 2024-02-22 Accent Therapeutics, Inc. Inhibitors of kif18a and uses thereof
CN119790049A (zh) * 2022-09-30 2025-04-08 楚浦创制（武汉）医药科技有限公司 2-氨基嘧啶类化合物及其应用、药用组合物
WO2024114730A1 (zh) * 2022-11-30 2024-06-06 微境生物医药科技(上海)有限公司 一种用于癌症治疗的药物组合物
EP4669309A1 (en) * 2023-02-23 2025-12-31 Volastra Therapeutics, Inc. SOLID FORMULATIONS AND POLYMORPHIC FORMS OF KIF18A INDOLIN INHIBITORS
WO2024188338A1 (zh) * 2023-03-16 2024-09-19 微境生物医药科技(上海)有限公司 Kif18a抑制剂
CN121909029A (zh) 2023-06-14 2026-04-21 沃拉斯查疗法公司 用kif18a的吲哚啉抑制剂治疗癌症的方法
WO2025190325A1 (zh) * 2024-03-13 2025-09-18 海南先声再明医药股份有限公司 Kif18a抑制剂和微管蛋白抑制剂的药物组合及用途

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6534309B1 (en) 2000-08-03 2003-03-18 Cytokinetics, Inc. Motor proteins and methods for their use
CA2432825A1 (en) 2000-12-15 2002-06-20 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
CA2485343A1 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
US7423018B2 (en) 2002-12-13 2008-09-09 University Of Massachusetts Kinesin-like proteins and methods of use
CN1835746A (zh) 2003-08-15 2006-09-20 默克公司 有丝分裂驱动蛋白抑制剂
US7504413B2 (en) 2004-05-06 2009-03-17 Cytokinetics, Inc. N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases
JP4836280B2 (ja) 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌を治療するためのキネシンスピンドルタンパク質（ｋｓｐ）阻害剤としてのｎ−（１−（１−ベンジル−４−フェニル−１ｈ−イミダゾール−２−イル）−２，２−ジメチルプロピル）ベンズアミド誘導体および関連化合物
JP2008509971A (ja) 2004-08-18 2008-04-03 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｅｇ５キネシンのインヒビターとして使用するためのベンゾチエノピリジン
WO2006114788A1 (en) 2005-04-25 2006-11-02 Ramot At Tel Aviv University Ltd. Kinesin polypeptides, polynucleotides encoding same and compositions and methods of using same
EP1942888A2 (en) 2005-11-02 2008-07-16 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US20100021420A1 (en) 2006-07-14 2010-01-28 Astex Therapeutics Limited Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
WO2008015265A1 (de) 2006-08-04 2008-02-07 Æterna Zentaris Gmbh Anthracen-derivate und deren verwendung zur behandlung gutartiger und bösartiger tumorerkrankungen
US20080051463A1 (en) 2006-08-04 2008-02-28 Aeterna Zentaris Gmbh Anthracene compounds and their use for treating benign and malignant tumor disorders
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
EP2295543A1 (en) 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the preparation of an influenza virus
WO2011085261A1 (en) 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors
JP5111626B2 (ja) 2011-01-14 2013-01-09 Ｎｔｎ株式会社 電動シートリクライニング用ころ軸受
CN102796103A (zh) 2011-05-23 2012-11-28 南京英派药业有限公司 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
WO2013188600A1 (en) 2012-06-12 2013-12-19 Washington University Copy number aberration driven endocrine response gene signature
JP6098406B2 (ja) 2013-07-17 2017-03-22 Ｊｆｅスチール株式会社 溶接接合部および溶接接合方法
JP6397410B2 (ja) 2013-08-09 2018-09-26 武田薬品工業株式会社 芳香環化合物
US20170095479A1 (en) 2014-05-29 2017-04-06 Merck Sharp & Dohme Corp. Methods for Treating Cancer with a WEE1 Inhibitor
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
TW201643138A (zh) 2015-04-17 2016-12-16 佛瑪治療公司 作為組蛋白脫乙醯基酶（ｈｄａｃ）抑制劑之３－螺－７－異羥肟酸四氫萘
CN106795149B (zh) 2015-05-05 2019-09-24 上海海雁医药科技有限公司 双环取代的苯磺酰胺衍生物、其制法与医药上的用途
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
BR112020000477A2 (pt) 2017-07-10 2020-07-21 Cornell University ataque à instabilidade cromossômica e sinalização de dna citosólico a jusante para tratamento de câncer
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
CN108768023B (zh) 2018-08-13 2020-01-07 珠海格力电器股份有限公司 转子组件及交替极电机
DE102018213662A1 (de) 2018-08-14 2020-02-20 Robert Bosch Gmbh Lautsprecher mit einem darin enthaltenen Leuchtelement
CN109039072B (zh) 2018-08-21 2020-09-08 南京南瑞继保电气有限公司 一种双极双向直流变换器及其控制方法和控制装置
CA3123227A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
MX2021007157A (es) * 2018-12-20 2021-08-16 Amgen Inc Heteroarilamidas utiles como inhibidores de kif18a.
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
PE20211475A1 (es) 2018-12-20 2021-08-05 Amgen Inc Inhibidores de kif18a
CA3132338A1 (en) 2019-04-05 2020-10-08 David Suhy Improved methods and compositions for synthetic biomarkers
CN113785076B (zh) 2019-05-03 2024-06-11 株式会社递希真 预测癌症预后的方法及其组合物
US20230093080A1 (en) 2019-07-15 2023-03-23 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2021026101A1 (en) * 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
CN114302880B (zh) 2019-08-02 2025-07-15 美国安进公司 Kif18a抑制剂
US12540129B2 (en) 2019-08-02 2026-02-03 Amgen Inc. KIF18A inhibitors
CA3147272A1 (en) * 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
EP4103045A4 (en) 2020-02-16 2024-08-14 Genetikaplus Ltd. Methods of therapeutic prognostication
US12187992B2 (en) 2020-02-19 2025-01-07 The Regents Of The University Of California Method and device for early cancer screening
TW202203919A (zh) 2020-04-14 2022-02-01 美商安進公司 用於治療贅生性疾病之ｋｉｆ１８ａ抑制劑
WO2021231413A1 (en) 2020-05-11 2021-11-18 University Of Vermont A treatment approach involving kif18a inhibition for chromosomally unstable tumors
EP4192957A4 (en) 2020-08-07 2024-09-04 Casma Therapeutics, Inc. Trpml modulators
WO2022214054A1 (en) 2021-04-09 2022-10-13 Nanjing University Conjugate and the preparing method and use thereof
CN113528509A (zh) 2021-06-01 2021-10-22 释科生物科技(广州)有限公司 一种用于预测胃癌免疫治疗的肿瘤微环境评分系统的构建方法以及分子探针
CA3224249A1 (en) 2021-06-25 2022-12-29 Hangzhou Innogate Pharma Co., Ltd. Compound as kif18a inhibitor
TW202321213A (zh) 2021-07-21 2023-06-01 美商安進公司 Ｋｉｆ１８ａ抑制劑化合物之鹽和固態形式
CN115772159A (zh) 2021-09-06 2023-03-10 微境生物医药科技(上海)有限公司 Kif18a抑制剂
CN115785068A (zh) 2021-09-10 2023-03-14 微境生物医药科技(上海)有限公司 Kif18a抑制剂
WO2023041055A1 (zh) 2021-09-16 2023-03-23 微境生物医药科技(上海)有限公司 Kif18a抑制剂
US20230117405A1 (en) 2021-09-22 2023-04-20 Volastra Therapeutics, Inc. Systems and methods for evaluation of chromosomal instability using machine-learning
WO2023088441A1 (zh) 2021-11-19 2023-05-25 微境生物医药科技(上海)有限公司 Kif18a抑制剂
JP2025515484A (ja) 2022-04-28 2025-05-15 ヴォラストラ セラピューティクス，インコーポレーテッド Ｋｉｆ１８ａを阻害するための化合物

Also Published As

Publication number Publication date
EP4392407A1 (en) 2024-07-03
US20240351984A1 (en) 2024-10-24
CL2024000560A1 (es) 2024-09-13
IL310863A (en) 2024-04-01
US20230147507A1 (en) 2023-05-11
MX2024002391A (es) 2024-06-03
WO2023028564A1 (en) 2023-03-02
US12084420B2 (en) 2024-09-10
KR20240109977A (ko) 2024-07-12
JP2024534840A (ja) 2024-09-26
TW202317092A (zh) 2023-05-01
CN119241504A (zh) 2025-01-03
AU2022334480A1 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
RU2701156C2 (ru) Азотсодержащие гетероциклические производные и их применение в фармацевтических препаратах
US12084420B2 (en) Indoline compounds for inhibiting KIF18A
AU2014225604B2 (en) Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
AU2022329230A1 (en) Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine
TWI804003B (zh) Tlr7/8拮抗劑及其用途
KR102653190B1 (ko) 고 활성 sting 단백질 작용제 화합물
CA3165238A1 (en) Kras mutant protein inhibitors
EP3686196B1 (en) Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor
AU2009200689A1 (en) Deazapurines and uses thereof
CA3172478A1 (en) Bcl-2 inhibitor
AU2016258188B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
EP3472131B1 (en) 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
KR20250023365A (ko) 알파 4 베타 7 인테그린 조정제 및 그의 용도
KR20220119597A (ko) 4원 고리 유도체의 개질제, 및 이의 제조 방법 및 용도
CA3231743A1 (en) Pyridinylacetamide derivatives as sodium channel activators
TW202540125A (zh) 雙環雜芳基化合物
WO2017156177A1 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
JP7182553B2 (ja) Ｒｏｒガンマ調節剤としての三環スルホン類
CA3181351A1 (en) Nampt modulators
TW202218661A (zh) 作為ｅｇｆｒ抑制劑的三環化合物
EA051754B1 (ru) Спироиндолиновые ингибиторы kif18a
CN106065018A (zh) 取代的吲哚化合物及其使用方法和用途
CN107922426B (zh) 四氢噁庚英吡啶化合物
HK40047619B (zh) 四元环类衍生物调节剂、其制备方法和应用
HK40047618B (zh) 苯并噻吩类衍生物调节剂、其制备方法和应用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250702

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250702